Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 1,737 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Synucleinopathy Clear all
Completed Not applicable Interventional

Expectation and Response to Levodopa and Acupuncture in Parkinson's Disease

NCT00692328
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Levodopa or acupuncture
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 80 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Nov 15, 2026, 4:42 AM EST
Completed Phase 1 Interventional

Allopregnanolone as a Regenerative Treatment for Parkinson's Disease

NCT06263010
View directory record Official record
Conditions
Parkinson Disease
Interventions
Allopregnanolone
Drug
Lead sponsor
Roberta Brinton
Other
Eligibility
40 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Nov 15, 2026, 4:42 AM EST
Not listed Not applicable Interventional

Exercise Targeting Cognitive Impairment in Parkinson's Disease

NCT02267785
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Skill-Based Exercise, Aerobic Exercise, Social Contact
Other
Lead sponsor
University of Southern California
Other
Eligibility
30 Years to 85 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 31, 2019 · Synced Nov 15, 2026, 4:42 AM EST
Not yet recruiting Not applicable Interventional

VC/VS for Apathy in PD

NCT06991335
View directory record Official record
Conditions
Parkinson Disease, Deep Brain Stimulation, Apathy
Interventions
Deep Brain Stimulation
Device
Lead sponsor
Nora Vanegas
Other
Eligibility
40 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Nov 15, 2026, 4:42 AM EST
Completed Phase 1Phase 2 Interventional Results available

Study of AMDX-2011P as a Retinal Tracer in Subjects With Neurodegenerative Diseases Associated With Amyloidogenic Proteinopathy

NCT05542576
View directory record Official record
Conditions
Parkinson Disease, Amyotrophic Lateral Sclerosis
Interventions
AMDX2011P
Drug
Lead sponsor
Amydis Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Newport Beach, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Nov 15, 2026, 4:42 AM EST
Terminated Phase 1 Interventional

Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia

NCT02589340
View directory record Official record
Conditions
Parkinson's Disease, Dyskinesias, Movement Disorders
Interventions
Buspirone, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 99 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Nov 15, 2026, 4:42 AM EST
Terminated Not applicable Interventional

Effects of an Independent Walking Program With Walking Poles in People With Parkinson Disease

NCT06908135
View directory record Official record
Conditions
Parkinson Disease
Interventions
Independent walking program using walking poles, Independent walking program without walking poles
Behavioral
Lead sponsor
Pacific Northwest University of Health Sciences
Other
Eligibility
Not listed
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Yakima, Washington
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Nov 15, 2026, 4:42 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Rifampin on the Metabolism of Istradefylline in Healthy Volunteers.

NCT02174250
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Istradefylline 40 mg, Rifampin 300mg BID + istradefylline 40mg Day 8 only
Drug
Lead sponsor
Kyowa Kirin Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Nov 15, 2026, 4:42 AM EST
Completed Phase 2 Interventional Results available

A Study of TAK-341 in Treatment of Multiple System Atrophy

NCT05526391
View directory record Official record
Conditions
Multiple System Atrophy
Interventions
Placebo, TAK-341
Drug
Lead sponsor
Takeda
Industry
Eligibility
40 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
7
States / cities
Farmington Hills, Michigan • Rochester, Minnesota • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Nov 15, 2026, 4:42 AM EST
Enrolling by invitation Phase 1 Interventional

Phase 1/2a Study of ANPD001 in Parkinson Disease

NCT06344026
View directory record Official record
Conditions
Parkinson Disease
Interventions
ANPD001, Custom Device
Biological · Device
Lead sponsor
Aspen Neuroscience
Industry
Eligibility
40 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
9
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Nov 15, 2026, 4:42 AM EST
Recruiting Not applicable Interventional

Remote Haptic Rehabilitation for Parkinson's Disease

NCT07457710
View directory record Official record
Conditions
Parkinson's Disease (PD)
Interventions
Haptic device, Non-haptic device
Device
Lead sponsor
Virginia Polytechnic Institute and State University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Blacksburg, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Nov 15, 2026, 4:42 AM EST
Completed Phase 1 Interventional Results available

An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of Ascending Doses of Lu AE04621 in Parkinson Disease Patients

NCT02649608
View directory record Official record
Conditions
Parkinson Disease
Interventions
0.04 mg Lu AE04621, 0.08 mg Lu AE04621, 0.2 mg Lu AE04621, 0.4 mg Lu AE04621, 0.6 mg Lu AE04621, 0.8 mg Lu AE04621, 1.0 mg Lu AE04621, 1.2 mg Lu AE04621
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
45 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
4
States / cities
Hallandale, Florida • Orlando, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Nov 15, 2026, 4:42 AM EST
Completed No phase listed Observational Accepts healthy volunteers

LRRK2 and Other Novel Exosome Proteins in Parkinson's Disease

NCT01860118
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
21 Years and older
Enrollment
601 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 11, 2018 · Synced Nov 15, 2026, 4:42 AM EST
Completed Phase 1 Interventional

Biomarker Assessments of Leukine During Treatment of Parkinson's Disease

NCT03790670
View directory record Official record
Conditions
Parkinson Disease
Interventions
sargramostim
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
35 Years to 85 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Nov 15, 2026, 4:42 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Studies of Brain and Body Interaction

NCT03672266
View directory record Official record
Conditions
Autistic Disorders Spectrum, Adhd, Asperger Syndrome, Alzheimer Disease, Parkinson, Tremor Essential, Dementia, Alzheimer Type, Lewy Body Dementia With Behavioral Disturbance (Disorder), Dementia With Lewy Bodies, Dementia Frontal
Interventions
Not listed
Lead sponsor
Rutgers University
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Nov 15, 2026, 4:42 AM EST
Completed Phase 3 Interventional Results available

Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease

NCT02610231
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
Istradefylline 20 mg or 40 mg
Drug
Lead sponsor
Kyowa Kirin Co., Ltd.
Industry
Eligibility
30 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
23
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Nov 15, 2026, 4:42 AM EST
Not listed Phase 2 Interventional

Long- Term Transcranial Direct Current Stimulation in Parkinson's Disease

NCT03638531
View directory record Official record
Conditions
Parkinson Disease
Interventions
Anodal tDCS, SHAM tDCS
Device
Lead sponsor
University of Nevada, Las Vegas
Other
Eligibility
60 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Oct 19, 2018 · Synced Nov 15, 2026, 4:42 AM EST
Completed Phase 2 Interventional

ACP-103 to Treat Parkinson's Disease

NCT00086294
View directory record Official record
Conditions
Parkinson's Disease, Dyskinesias
Interventions
Intravenous Levodopa, ACP-103
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
30 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Nov 15, 2026, 4:42 AM EST
Terminated No phase listed Observational

Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Ilera Specific Products

NCT03886753
View directory record Official record
Conditions
ALS, Autism Spectrum Disorder, Cancer, Spasticity, Muscle, Dyskinetic Syndrome, Epilepsy, Glaucoma, Huntington Disease, Inflammatory Bowel Disease (IBD), Multiple Sclerosis, Neuropathy, Opioid Use, Parkinson Disease, HIV/AIDS, Ptsd, Intractable Pain, Sickle Cell Disease, Terminal Illness
Interventions
Registry, PK microsampling of blood
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Nov 15, 2026, 4:42 AM EST
Completed Phase 3 Interventional

Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations

NCT00203034
View directory record Official record
Conditions
Parkinson's Disease
Interventions
rasagiline mesylate, 1.0 mg rasagiline mesylate, Placebo
Drug · Other
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
30 Years and older
Enrollment
472 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
4
States / cities
Chicago, Illinois • New York, New York • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2010 · Synced Nov 15, 2026, 4:42 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

VOCALE LBD+ for Caregivers of Persons With Lewy Body Dementia

NCT05622734
View directory record Official record
Conditions
Caregiver Burden, Lewy Body Disease, Stress, Skill, Coping
Interventions
VOCALE LBD+
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Nov 15, 2026, 4:42 AM EST
Terminated Not applicable Interventional Results available

Effect of Lower Extremity Ankle Foot Orthoses in Parkinson's Disease

NCT01798927
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Ankle foot orthosis
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
50 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2015 · Synced Nov 15, 2026, 4:42 AM EST
Terminated Phase 2 Interventional Results available

Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations

NCT02687542
View directory record Official record
Conditions
Parkinson Disease
Interventions
Placebo, PF-06649751 low dose (1 mg QD), PF-06649751 middle dose 1 (3 mg QD), PF-06649751 middle dose 2 (7 mg QD), PF-06649751 high dose (15 mg QD)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 85 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
33
States / cities
Phoenix, Arizona • Arcadia, California • Loma Linda, California + 26 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Nov 15, 2026, 4:42 AM EST
Completed Phase 1 Interventional

PF 06412562 in Subjects With Advanced Stage Parkinson's Disease

NCT03665454
View directory record Official record
Conditions
Parkinson Disease
Interventions
PF-06412562, Standard of Care Placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
Not listed
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Nov 15, 2026, 4:42 AM EST